A number of other brokerages have also weighed in on ZTS. Morgan Stanley lowered shares of Zoetis from an overweight rating to an equal weight rating and set a $70.00 price objective for the company. in a report on Monday, March 19th. They noted that the move was a valuation call. Jefferies Group set a $97.00 price objective on shares of Zoetis and gave the stock a buy rating in a report on Monday, February 26th. ValuEngine upgraded shares of Zoetis from a hold rating to a buy rating in a report on Monday, April 2nd. Deutsche Bank boosted their price objective on shares of Zoetis from $76.00 to $78.00 and gave the stock a hold rating in a report on Friday, February 16th. Finally, Barclays set a $77.00 price objective on shares of Zoetis and gave the stock a hold rating in a report on Saturday, February 17th. One analyst has rated the stock with a sell rating, six have issued a hold rating and fourteen have issued a buy rating to the company’s stock. Zoetis currently has a consensus rating of Buy and a consensus price target of $80.94.
Shares of ZTS opened at $80.97 on Thursday. The company has a market capitalization of $39,291.02, a PE ratio of 33.74, a price-to-earnings-growth ratio of 1.81 and a beta of 0.96. The company has a debt-to-equity ratio of 2.77, a current ratio of 3.85 and a quick ratio of 2.55. Zoetis has a fifty-two week low of $52.36 and a fifty-two week high of $85.73.
The company also recently declared a quarterly dividend, which will be paid on Friday, June 1st. Investors of record on Friday, April 20th will be issued a dividend of $0.126 per share. The ex-dividend date is Thursday, April 19th. This represents a $0.50 dividend on an annualized basis and a yield of 0.62%. Zoetis’s dividend payout ratio is currently 20.83%.
In other Zoetis news, EVP Roxanne Lagano sold 35,663 shares of the company’s stock in a transaction on Wednesday, February 21st. The shares were sold at an average price of $81.02, for a total value of $2,889,416.26. Following the completion of the transaction, the executive vice president now directly owns 49,919 shares in the company, valued at approximately $4,044,437.38. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Heidi C. Chen sold 7,383 shares of the company’s stock in a transaction on Friday, March 16th. The stock was sold at an average price of $84.71, for a total transaction of $625,413.93. Following the completion of the transaction, the insider now owns 20,162 shares of the company’s stock, valued at $1,707,923.02. The disclosure for this sale can be found here. Insiders have sold a total of 112,952 shares of company stock valued at $9,219,843 over the last quarter. 0.31% of the stock is currently owned by company insiders.
A number of hedge funds and other institutional investors have recently modified their holdings of ZTS. Harel Insurance Investments & Financial Services Ltd. bought a new position in Zoetis in the 4th quarter worth $108,000. Steward Partners Investment Advisory LLC bought a new position in Zoetis in the 3rd quarter worth $114,000. We Are One Seven LLC bought a new position in Zoetis in the 4th quarter worth $120,000. Premia Global Advisors LLC bought a new position in Zoetis in the 4th quarter worth $122,000. Finally, Icon Wealth Partners LLC bought a new position in Zoetis in the 4th quarter worth $127,000. Institutional investors and hedge funds own 92.35% of the company’s stock.
TRADEMARK VIOLATION WARNING: This story was published by Ticker Report and is owned by of Ticker Report. If you are reading this story on another domain, it was illegally copied and republished in violation of United States & international trademark and copyright legislation. The correct version of this story can be accessed at https://www.tickerreport.com/banking-finance/3342280/zoetis-zts-given-new-89-00-price-target-at-credit-suisse-group.html.
Zoetis Inc is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a business, commercializing products across eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock) and dogs, cats and horses (collectively, companion animals), and within five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals.
Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.